Highlights Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
12.07 ^USD	+0.92%		-3.75%	-20.33%

05-08	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating	MT
05-07	Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Zentalis Pharmaceuticals, Inc. Announces CFO Changes	04-11	CI
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024	04-02	CI
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	01-08	CI
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Westport Brief: Announcing Resignation of David Johnson, Chief Executive Officer, and Names Interim CEO	23-08-22	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Westport Fuel Systems Down 5.7% After Hours as Its Q2 Loss Widens on Higher Costs Even as Revenue Rose to a Record	23-08-08	MT
Zentalis Pharmaceuticals, Inc. Enters into an Agreement to Terminate Its Collaboration and License Agreements with Zentera Therapeutics	23-06-15	CI
Zentalis Pharmaceuticals, Inc. Announces Potential for Azenosertib (Zn-C3) to Address Large Unmet Need Across an Array of Cancers	23-06-06	CI
Zentalis Announces Presentation of Positive Phase 1B Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy	23-05-25	CI
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Zentalis Pharmaceuticals, Inc. Presents Positive Clinical Data in Ovarian Cancer Combining Azenosertib and Chemotherapy, Including Clinical Support for Cyclin E1 Expression as Predictive Marker for Clinical Benefit from Azenosertib At the 2023 ASCO Annual Meeting	23-04-26	CI
Zentalis Pharmaceuticals Announces Preclinical Data Supporting Cyclin E1 as Predictive Marker for Azenosertib Treatment at AACR Annual Meeting 2023	23-04-17	CI
Westport Signs Third Global Heavy-Duty OEM Collaboration Agreement	23-03-06	MT
Zentalis Pharmaceuticals' Fiscal 2022 Net Loss Widens	23-03-01	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
Zentalis Pharmaceuticals Q3 Loss Widens; Shares Drop	22-11-09	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Highlights

Filters